Ascendis Pharma A/S

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ascendis Pharma A/S sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 4 currently recruiting 4 completed early-phase tilt top decile by trial count

Ascendis Pharma A/S: 9 sponsored US clinical trials, 4 recruiting.

Ascendis Pharma A/S sponsors 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Short Stature Homeobox Gene Mutation, with 1 trials.

Top-decile sponsor footprint

Ascendis Pharma A/S ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)

NCT07264634
RECRUITING

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494
RECRUITING Phase 3

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
RECRUITING Phase 2

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

NCT06079398
TERMINATED Phase 2

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

NCT05980598
COMPLETED Phase 2

A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia

NCT04085523
COMPLETED Phase 2

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

NCT04009291
COMPLETED

A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

NCT03875534
COMPLETED Phase 3

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

NCT03344458

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 2

Therapeutic Areas

Short Stature Homeobox Gene Mutation 1
Small for Gestational Age at Delivery 1
Turner Syndrome 1
Achondroplasia 1
Idiopathic Short Stature 1
Hypoparathyroidism 1

What is open in the Ascendis Pharma A/S pipeline

4 recruiting of 9 indexed (44% open); 4 completed (44%).

Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Short Stature Homeobox Gene Mutation (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ascendis Pharma A/S: open-pipeline peers nationwide

Peers matched on 9 registered trials and 44% open enrollment, not the therapeutic-area sidebar.

Ascendis Pharma A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 51015202530 0%10%20%30%40%50% Total trials Recruiting share Ascendis Pharma A/S4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAmerican Heart AssociationCullinan TherapeuticsMarquette UniversityPalvella Therapeutics
Ascendis Pharma A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ascendis Pharma A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 44% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ascendis Pharma A/S page

9 registered trials is a research-attention snapshot, not an endorsement of Ascendis Pharma A/S or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ascendis Pharma A/S pipeline card: 9 registered trials from official public datasets.Report a data error.